Second Fosamax Bellwether Case Ends In Unanimous Verdict For Defendant Merck

NEW YORK — (Mealey’s) The second federal Fosamax bellwether trial ended in a defense verdict May 6 when a jury in the U.S. District Court for the Southern District of New York unanimously found that the plaintiff did not suffer from osteonecrosis of the jaw (ONJ) as of March 31, 2004, a date...

Jury Awards Plaintiff $285,000 In 5th Fosamax MDL Trial But Finds No Design Defect

NEW YORK - (Mealey's) A New York federal jury on Feb. 5 ordered Novartis Pharmaceuticals Corp. to pay $285,000 to a plaintiff for allegedly failing to warn her or her doctor that Fosamax carries a risk of osteonecrosis of the jaw (ONJ) ( In Re: Fosamax Products Liability Litigation , MDL Docket No...